马西替坦/他达拉非单片联合治疗肺动脉高压的随机试验
A DUE 3期研究纳入187例WHO功能II-III级肺动脉高压患者,随机接受马西替坦/他达拉非固定剂量单片联合、马西替坦10mg或他达拉非40mg单药治疗。第16周时联合组肺血管阻力较两单药组分别显著降低29%和28%,安全性与单药成分一致。
要点
- 马西替坦/他达拉非单片联合较单药显著降低肺血管阻力。
- 联合组因不良事件停药、严重不良事件及贫血、低血压、水肿更常见。
- 支持该单片联合用于初治及升级至双联治疗。
核心结论
- 马西替坦/他达拉非固定剂量单片联合较各自单药显著改善肺动脉高压患者的肺血管阻力。
- 安全性和耐受性与各单药成分一致。
研究设计与样本
- 多中心、双盲、适应性3期A DUE研究,纳入187例WHO功能II-III级肺动脉高压患者。
- 随机分为马西替坦/他达拉非单片联合组108例、马西替坦10mg组35例、他达拉非40mg组44例。
主要发现
- 第16周肺血管阻力联合组较马西替坦组降低29%(几何均值比0.71,95%CL 0.61-0.82,P<0.0001)。
- 联合组较他达拉非组降低28%(几何均值比0.72,95%CL 0.64-0.80,P<0.0001)。
- 联合组有3例死亡,判定与治疗无关。
- 因不良事件停药、严重不良事件及贫血、低血压、水肿等特别关注事件在联合组更频繁。
临床怎么用
- 马西替坦/他达拉非单片联合可作为肺动脉高压初治及升级至双联治疗的每日一次单片方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endothelin receptor antagonist (ERA) and phosphodiesterase 5 inhibitor (PDE5i) combination therapy is recommended for low-/intermediate-risk pulmonary arterial hypertension (PAH) patients. A fixed-dose combination of the ERA macitentan and PDE5i tadalafil (M/T FDC) in a once-daily, single tablet would simplify treatment. OBJECTIVES: The multicenter, double-blind, adaptive phase 3 A DUE study investigated the efficacy and safety of M/T FDC vs macitentan 10 mg and vs tadalafil 40 mg monotherapies in PAH patients, including treatment-naïve and prior ERA or PDE5i monotherapy-treated patients. METHODS: World Health Organization functional class II-III patients were randomized to M/T FDC, macitentan, or tadalafil depending on their PAH treatment (treatment-naïve, ERA, or PDE5i monotherapy) at baseline. The primary endpoint was change in pulmonary vascular resistance (PVR) at week 16. RESULTS: In total, 187 patients were randomized to single-tablet M/T FDC (n = 108), macitentan (n = 35), or tadalafil (n = 44). PVR reduction with M/T FDC was significantly greater vs macitentan (29%; geometric mean ratio 0.71; 95% CL: 0.61-0.82; P < 0.0001) and vs tadalafil (28%; geometric mean ratio 0.72; 95% CL: 0.64-0.80; P < 0.0001). Three patients died in the M/T FDC arm (judged unrelated to treatment). Adverse events (AEs) leading to discontinuation, serious AEs, and those of special interest (anemia, hypotension, and edema) were more frequent with M/T FDC. CONCLUSIONS: Macitentan and tadalafil FDC significantly improved PVR vs monotherapies in PAH patients, with a safety and tolerability profile consistent with the individual components. The A DUE study supports M/T FDC as a once-daily, single-tablet combination for initial therapy and escalation to double combination therapy in patients with PAH. (Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension [PAH]) [A DUE]; NCT03904693).
引用
- Grünig E, Jansa P, Fan F, et al. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2024. PMID: 38267108. doi:10.1016/j.jacc.2023.10.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。